Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy

This Medical Letter review describes how tafamidis prevents transthyretin protein complexes from disocciating into amyloid fibrils, and its recent approval in 2 different formulations (Vyndaqel and Vyndamax) for treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Source: JAMA - Category: General Medicine Source Type: research